QPPV.COM KNOWLEDGE ASSESSMENT

Additional Pharmacovigilance Activities

Test your understanding of the concepts covered by Additional Pharmacovigilance Activities in the EU Risk Management Plan.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which factor is most relevant when deciding whether a pregnancy registry can provide useful evidence about rare congenital anomalies?
Question 2 of 10 Which design is most directly suited to assessing off-label use and adherence to risk minimisation measures?
Question 3 of 10 Which inspection finding most clearly indicates weak integration of an additional activity into the RMP?
Question 4 of 10 Why should confounding and bias be addressed explicitly in the design rationale?
Question 5 of 10 What is the most defensible way to justify an additional activity in RMP text?
Question 6 of 10 Which documentation would most directly support an inspector's assessment of whether a regulatory commitment is being controlled?
Question 7 of 10 Which example best illustrates a risk minimisation effectiveness study?
Question 8 of 10 A suspected adverse event may be a product-specific risk or a class-wide effect. Which approach most directly addresses this distinction?
Question 9 of 10 A company proposes a large, resource-intensive registry, but a well-maintained database cohort could answer the safety question with adequate validity. What is the most appropriate interpretation?
Question 10 of 10 Which governance arrangement is particularly appropriate when an interventional study has important safety monitoring needs?

Select an answer to continue.

QPPV.com